Heparin-Induced Thrombocytopenia

History of heparin-induced thrombocytopenia; differential diagnosis of acute thrombocytopenia; clinical picture of heparin-induced thrombocytopenia; frequency of heparin-induced thrombocytopenia; nonimmune heparin/platelet interactions -implications for the pathogenesis of heparin-induced thrombocytopenia; heparin-dependent antigens in heparin-induced thrombocytopenia; molecular immunopathogenesis of heparin-induced thrombocytopenia; role of sulfated polysaccharides in the pathogenesis of heparin-induced thrombocytopenia; the platelet Fc receptor in heparin-induced thrombocytopenia; immune vascular injury in heparin-induced thrombocytopenia; laboratory testing for heparin-induced thrombocytopenia; pseudo-heparin-induced thrombocytopenia; treatment of heparin-induced thrombocytopenia -an overview; danaparoid for the treatment of heparin-induced thrombocytopenia; recombinant hirudin for the treatment of heparin-induced thrombocytopenia; haemodialysis in heparin-induced thrombocytopenia; management of cardiopulmonary bypass anticoagulation in patients with heparin-induced thrombocytopenia; legal aspects of heparin-induced thrombocytopenia; appendices -clinical rules for the use of anticoagulants, treatment recommendations, danaparoid dosing schedules, dosing schedules for r-hirudin treatment of patients with HIT.